Skip to content
10-Q

Quarterly Report

ULTRAGENYX PHARMACEUTICAL INC. RARE

0001193125-26-206960

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 98.49M sh
Shares Diluted Q1 2026 · Mar 31, 2026 100.6M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 96.3M sh
Capex Q1 2026 · Mar 31, 2026 $1M
Capex restated Q1 2026 · Mar 31, 2025 $1M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$197M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$166M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $175M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $421M
Cash And Equivalents restated Q1 2026 · Mar 31, 2025 $127M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$236M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$80M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 $144M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 $255M
Current Liabilities Q1 2026 · Mar 31, 2026 $325M
Current Liabilities Q1 2026 · Dec 31, 2025 $384M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.53B
Total Liabilities Q1 2026 · Dec 31, 2025 $1.61B
Current Assets Q1 2026 · Mar 31, 2026 $657M
Current Assets Q1 2026 · Dec 31, 2025 $951M
Total Assets Q1 2026 · Mar 31, 2026 $1.3B
Total Assets Q1 2026 · Dec 31, 2025 $1.53B
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.84
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.57
Eps Basic Q1 2026 · Mar 31, 2026 −$1.84
Eps Basic Q1 2026 · Mar 31, 2025 −$1.57
Sga Expense Q1 2026 · Mar 31, 2026 $88M
Sga Expense restated Q1 2026 · Mar 31, 2025 $87M
Rd Expense Q1 2026 · Mar 31, 2026 $187M
Rd Expense restated Q1 2026 · Mar 31, 2025 $166M
Net Income Q1 2026 · Mar 31, 2026 −$185M
Net Income restated Q1 2026 · Mar 31, 2025 −$151M
Operating Income Q1 2026 · Mar 31, 2026 −$169M
Operating Income restated Q1 2026 · Mar 31, 2025 −$143M
Revenue Q1 2026 · Mar 31, 2026 $136M
Revenue restated Q1 2026 · Mar 31, 2025 $139M